Mauro D’Amico

1.9k total citations · 1 hit paper
32 papers, 1.2k citations indexed

About

Mauro D’Amico is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Mauro D’Amico has authored 32 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in Mauro D’Amico's work include Breast Cancer Treatment Studies (10 papers), Cancer Treatment and Pharmacology (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). Mauro D’Amico is often cited by papers focused on Breast Cancer Treatment Studies (10 papers), Cancer Treatment and Pharmacology (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). Mauro D’Amico collaborates with scholars based in Italy, United Kingdom and United States. Mauro D’Amico's co-authors include Luca Boni, Alberto Zaniboni, Alfredo Falcone, Fotios Loupakis, Cristina Granetto, Giuseppe Tonini, Chiara Cremolini, Sara Lonardi, Monica Ronzoni and Gianluca Tomasello and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Mauro D’Amico

30 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

2015 733 citations Chiara Cremolini, Fotios Loupakis et al. The Lancet Oncology profile →

Peers

Mauro D’Amico

ONCOL

PRM

PFM

HEPAT

Swantje Held Germany

Belguendouz Bendahmane France

Rosella Spadi Italy

Saima Sharif United States

M. Rother Canada

Marie‐Pierre Galais France

A. Misino Italy

Tadamichi Denda Japan

Daniel Rauch Switzerland

L. Leong United States

Swantje Held Germany

Mauro D’Amico

920 ×0.9

ONCOL

444 ×1.1

PRM

210 ×0.7

318 ×1.1

PFM

278 ×1.1

HEPAT

Citations per year, relative to Mauro D’Amico Mauro D’Amico (= 1×) peers Swantje Held

Countries citing papers authored by Mauro D’Amico

Since Specialization

Citations

This map shows the geographic impact of Mauro D’Amico's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mauro D’Amico with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mauro D’Amico more than expected).

Fields of papers citing papers by Mauro D’Amico

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mauro D’Amico. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mauro D’Amico. The network helps show where Mauro D’Amico may publish in the future.

Co-authorship network of co-authors of Mauro D’Amico

This figure shows the co-authorship network connecting the top 25 collaborators of Mauro D’Amico. A scholar is included among the top collaborators of Mauro D’Amico based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mauro D’Amico. Mauro D’Amico is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Aurilio, Gaetano, Davide Serrano, Matteo Lazzeroni, et al.. (2025). Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention. npj Breast Cancer. 11(1). 53–53.

Merlano, Marco, Marco Ravanelli, Andrea Alberti, et al.. (2023). Muscle quality and not quantity as a predictor of survival in head and neck squamous cell carcinoma. Oral Oncology. 145. 106540–106540. 6 indexed citations

Censi, Andrea De, Davide Serrano, Sara Gandini, et al.. (2022). A randomized presurgical trial of alternative dosing of exemestane in postmenopausal women with early-stage ER-positive breast cancer.. Journal of Clinical Oncology. 40(16_suppl). 519–519. 1 indexed citations

DeCensi, Andrea, Harriet Johansson, Matteo Puntoni, et al.. (2021). Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial. npj Breast Cancer. 7(1). 34–34. 9 indexed citations

Guerrieri‐Gonzaga, Aliana, Davide Serrano, Katherine D. Crew, et al.. (2021). Alternative dosing of exemestane in postmenopausal women with ER-positive breast cancer. Design and methods of a randomized presurgical trial. Contemporary Clinical Trials. 107. 106498–106498. 2 indexed citations

Lazzeroni, Matteo, Matteo Puntoni, Nicoletta Provinciali, et al.. (2019). Estimating the magnitude of clinical benefit of systemic therapy in patients with DCIS or pre-invasive disease of the breast. The Breast. 48. S39–S43. 4 indexed citations

Puntoni, Matteo, Marco Piccininno, Arnoldo Piccardo, et al.. (2016). Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer. Translational Oncology. 9(6). 600–605. 9 indexed citations

Clavarezza, Matteo, Matteo Puntoni, Alessandra Gennari, et al.. (2016). Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials. Clinical Cancer Research. 22(18). 4594–4603. 27 indexed citations

Cremolini, Chiara, Fotios Loupakis, Sara Lonardi, et al.. (2015). Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Annals of Oncology. 26(6). 1188–1194. 135 indexed citations

10.

Cremolini, Chiara, Fotios Loupakis, Carlotta Antoniotti, et al.. (2015). FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. The Lancet Oncology. 16(13). 1306–1315. 733 indexed citations breakdown →

11.

Passamonti, Basilio, Simonetta Bulletti, Daniela Gustinucci, et al.. (2014). Cervical Human Papilloma Virus (HPV) DNA Primary Screening Test Results of the Experience of a Regional Laboratory in Central Italy. Value in Health. 17(7). A614–A614.

12.

D’Amico, Mauro, Matteo Puntoni, Matteo Clavarezza, et al.. (2014). An observational study of nasal cavity toxicity in cancer patients treated with bevacizumab. Expert Opinion on Drug Safety. 13(11). 1437–1442. 7 indexed citations

13.

Defferrari, Carlotta, Mauro D’Amico, Arnoldo Piccardo, et al.. (2012). A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer. Journal of Ovarian Research. 5(1). 17–17. 3 indexed citations

14.

Giorgio, Elisa, C. Caroti, Francesca Mattioli, et al.. (2011). Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation. Cancer Chemotherapy and Pharmacology. 68(5). 1355–1361. 12 indexed citations

15.

Gennari, Alessandra, Martin R. Stockler, Matteo Puntoni, et al.. (2011). Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Journal of Clinical Oncology. 29(16). 2144–2149. 134 indexed citations

16.

D’Amico, Mauro, et al.. (2009). Cervical cancer screening programs in low-income communities. Experiences from Ecuador. Low cost detection of HPV infection in a developing country.. PubMed. 101(2). 76–9. 4 indexed citations

17.

Orlando, Laura, Marco Colleoni, Palma Fedele, et al.. (2007). Management of advanced breast cancer. Annals of Oncology. 18. vi74–vi76. 20 indexed citations

18.

Cinieri, Saverio, Laura Orlando, Palma Fedele, et al.. (2007). Adjuvant strategies in breast cancer: new prospectives, questions and reflections at the end of 2007 St Gallen International Expert Consensus Conference. Annals of Oncology. 18. vi63–vi65. 20 indexed citations

19.

Palmieri, Salvatore, Alfonso Maria D’Arco, Giuseppina Mele, et al.. (2006). An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid leukemia of older adult patients. Annals of Oncology. 17(7). 1146–1151. 6 indexed citations

20.

Mastro, Lucia Del, Paolo Bruzzi, Guido Nicolò, et al.. (2005). HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. British Journal of Cancer. 93(1). 7–14. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact